Tag: Ozempic Outlook

Name: CapWolf
Rating: 4.9 (351 reviews)

Why Novo Nordisk’s GLP-1 Growth Is Slowing: Key Insights

Novo Nordisk’s Ozempic is losing ground in the GLP-1 market. What’s behind the slowdown, and can it recover? Dive into...

05/08/2025

3 views

Novo Nordisk shares tanked 15% after slashing 2025 guidance. What's causing the dip in Wegovy and Ozempic sales? Dive into...

29/07/2025

3 views